Biogen to acquire novel clinical-stage asset from Pfizer14 Jan 2020
PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.
Biogen has agreed to acquire from Pfizer PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases.
In particular, Biogen plans to develop the Phase I asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). The purchase will include an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments, as well as tiered royalties in the high single digits to sub-teens.
“This asset is highly complementary to our existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases,” said Alfred Sandrock Jr., Executive Vice President, Research and Development and Chief Medical Officer at Biogen. “Many patients with Alzheimer’s and Parkinson’s suffer from debilitating sleep disorders and agitation, and we believe that the regulation of the circadian rhythm may hold promise in addressing these challenging behavioral and neurological symptoms.”
CK1 is a key regulator of the ‘central clock,’ the suprachiasmatic nucleus of the hypothalamus, that controls circadian rhythm and impacts nearly all vital physiology and metabolism. The disruption of circadian rhythm is associated with various psychiatric and neurological diseases, including certain important symptoms of AD and PD.
Sundowning is a symptom that impacts 20% or more of AD patients who become confused, anxious, aggressive, agitated or restless later in the day. ISWRD is a circadian rhythm disorder where patients experience fragmented nighttime sleep leading to daytime sleepiness, severe fatigue and difficulty with activities of daily living.
It is one of the non-motor symptoms of PD, and usually increases in frequency over the course of the disease and disability progression. Biogen will explore the potential of PF-05251749 to improve behavioral disturbances of Sundowning in AD by correcting circadian rhythm, as well as its potential to treat symptoms of ISWRD to improve daytime wakefulness, sleep quality, behavior and daily function.
PF-05251749 has previously demonstrated an acceptable safety profile and proof of mechanism in a Phase Ia clinical study. Biogen aims to initiate a Phase Ib study in Q4 2020.
Pioneer in Phenylketonuria to begin clinical trial with gene therapy
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.Read more
French regulator agrees to partial resumption of Tellomak trial patient recruitment
14 Jan 2020
The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...Read more
Partnership formed to develop and commercialise ready-to-use medicine
13 Jan 2020
The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.Read more
ReadCoor to commercially launch spatial sequencing platform
10 Jan 2020
Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.Read more
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
NIH researchers discover new autoinflammatory disease
3 Jan 2020
Mutations in the RIPK1 gene responsible for CRIA syndrome.Read more
BioAscent scientists help identify potential new treatments for cancer
30 Dec 2019
Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.Read more
NIH launches first US clinical trial of patient-derived stem cell therapy to replace dying cells in retina
13 Dec 2019
NEI-led study to test safety of treatment for a form of age-related macular degeneration that currently lacks treatment.Read more
Sanofi bolsters its immuno-oncology pipeline for $2.5B
6 Dec 2019
Lead asset THOR-707 being explored across multiple solid tumor types alone and in combination with immune checkpoint inhibitors and other future IO combinations.Read more
Catalent to partner with Ethicann on new fast-dissolve cannabinoid-based treatment
4 Dec 2019
Program will initially focus on using Catalent’s orally disintegrating tablet technology to develop a combination pharmaceutical-grade CBD and THC product that, if approved, would treat patients suffering from MS spasticity.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation